Altered Sphingolipid Metabolism is Associated with Osimertinib Resistance in Nonsmall-Cell Lung Cancer
Journal of Proteome Research · 01.05.2026 · 25 (5) · 2569-2580
DOI: 10.1021/acs.jproteome.6c00216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, online erschienen am 16.04.2026. Verfasst von Julia Babuta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, AstraZeneca UK, NIHR Imperial Biomedical Research Centre.
Abstract (Originalsprache)
Nonsmall-cell lung cancer (NSCLC) accounts for more than 80% of lung cancer cases. Epidermal growth factor receptor mutations (EGFRm) occur in 15 and 40% of NSCLC in Western and Asian populations, respectively. Current treatment for advanced NSCLC targets EGFRm with tyrosine kinase inhibitors (TKIs). Osimertinib is a third-generation EGFR-TKI now used as a first-line treatment in advanced/metastatic NSCLC; however, drug resistance frequently develops. Dysregulation of metabolism has been suggested to play a role in the development of drug resistance. Here, we investigated the role of lipid metabolism in the development of osimertinib resistance (OR) using pharmacologically-induced resistant cellular models. We used a multiomics approach, combining lipidomics with proteomics analyses. We found alterations in processes relating to metabolism, such as dysregulated sphingolipid metabolism. In particular, we identified that OR lines reduce free ceramides in favor of complex glycosphingolipids. Mechanistically, this metabolic shift avoids ceramide-mediated apoptosis via caspase-3 activation. Importantly, when we combined osimertinib with D-PDMP, an inhibitor of the key enzyme responsible for the conversion of ceramide to glucosylceramide, we increased the sensitivity to osimertinib. Overall, we have identified the glycosphingolipid metabolic pathway as a potential therapeutic target to reinstate sensitivity to osimertinib in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom.
- Department of Surgery and Cancer, Imperial College London, London W12 0NN, United Kingdom.
- MRC Laboratory of Medical Sciences, London W12 0NN, United Kingdom.
- AstraZeneca, Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
ORCID-Profile: Flora McKinney, Hector Keun, Zoe Hall
Förderung
- Medical Research Council
- AstraZeneca UK
- NIHR Imperial Biomedical Research Centre
Zitieren
APA
Babuta, J., Gruevska, A., Wickremesinghe, C., Montoya, A., Roumelioti, G., Shliaha, P., Balcells, C., McKinney, F., Bray, C., Athersuch, T., Martin, M., Keun, H., & Hall, Z. (2026). Altered Sphingolipid Metabolism is Associated with Osimertinib Resistance in Nonsmall-Cell Lung Cancer. Journal of Proteome Research, 25(5), 2569-2580. https://doi.org/10.1021/acs.jproteome.6c00216
Vancouver
Babuta J, Gruevska A, Wickremesinghe C, Montoya A, Roumelioti G, Shliaha P, et al. Altered Sphingolipid Metabolism is Associated with Osimertinib Resistance in Nonsmall-Cell Lung Cancer. Journal of Proteome Research. 2026;25(5):2569-2580. doi:10.1021/acs.jproteome.6c00216
BibTeX
@article{Babuta2026,
author = {Babuta, Julia and Gruevska, Aleksandra and Wickremesinghe, Chiharu and Montoya, Alex and Roumelioti, Georgia and Shliaha, Pavel and Balcells, Cristina and McKinney, Flora and Bray, Chandler and Athersuch, Toby and Martin, Matthew and Keun, Hector and Hall, Zoe},
title = {Altered Sphingolipid Metabolism is Associated with Osimertinib Resistance in Nonsmall-Cell Lung Cancer},
journal = {Journal of Proteome Research},
year = {2026},
volume = {25},
number = {5},
pages = {2569--2580},
doi = {10.1021/acs.jproteome.6c00216}
}
EUVIMED